Using Smartphones and Wearable Devices to Monitor Behavioral Changes During COVID-19.


Journal

Journal of medical Internet research
ISSN: 1438-8871
Titre abrégé: J Med Internet Res
Pays: Canada
ID NLM: 100959882

Informations de publication

Date de publication:
25 09 2020
Historique:
received: 08 05 2020
accepted: 26 07 2020
revised: 20 07 2020
pubmed: 3 9 2020
medline: 6 10 2020
entrez: 3 9 2020
Statut: epublish

Résumé

In the absence of a vaccine or effective treatment for COVID-19, countries have adopted nonpharmaceutical interventions (NPIs) such as social distancing and full lockdown. An objective and quantitative means of passively monitoring the impact and response of these interventions at a local level is needed. We aim to explore the utility of the recently developed open-source mobile health platform Remote Assessment of Disease and Relapse (RADAR)-base as a toolbox to rapidly test the effect and response to NPIs intended to limit the spread of COVID-19. We analyzed data extracted from smartphone and wearable devices, and managed by the RADAR-base from 1062 participants recruited in Italy, Spain, Denmark, the United Kingdom, and the Netherlands. We derived nine features on a daily basis including time spent at home, maximum distance travelled from home, the maximum number of Bluetooth-enabled nearby devices (as a proxy for physical distancing), step count, average heart rate, sleep duration, bedtime, phone unlock duration, and social app use duration. We performed Kruskal-Wallis tests followed by post hoc Dunn tests to assess differences in these features among baseline, prelockdown, and during lockdown periods. We also studied behavioral differences by age, gender, BMI, and educational background. We were able to quantify expected changes in time spent at home, distance travelled, and the number of nearby Bluetooth-enabled devices between prelockdown and during lockdown periods (P<.001 for all five countries). We saw reduced sociality as measured through mobility features and increased virtual sociality through phone use. People were more active on their phones (P<.001 for Italy, Spain, and the United Kingdom), spending more time using social media apps (P<.001 for Italy, Spain, the United Kingdom, and the Netherlands), particularly around major news events. Furthermore, participants had a lower heart rate (P<.001 for Italy and Spain; P=.02 for Denmark), went to bed later (P<.001 for Italy, Spain, the United Kingdom, and the Netherlands), and slept more (P<.001 for Italy, Spain, and the United Kingdom). We also found that young people had longer homestay than older people during the lockdown and fewer daily steps. Although there was no significant difference between the high and low BMI groups in time spent at home, the low BMI group walked more. RADAR-base, a freely deployable data collection platform leveraging data from wearables and mobile technologies, can be used to rapidly quantify and provide a holistic view of behavioral changes in response to public health interventions as a result of infectious outbreaks such as COVID-19. RADAR-base may be a viable approach to implementing an early warning system for passively assessing the local compliance to interventions in epidemics and pandemics, and could help countries ease out of lockdown.

Sections du résumé

BACKGROUND
In the absence of a vaccine or effective treatment for COVID-19, countries have adopted nonpharmaceutical interventions (NPIs) such as social distancing and full lockdown. An objective and quantitative means of passively monitoring the impact and response of these interventions at a local level is needed.
OBJECTIVE
We aim to explore the utility of the recently developed open-source mobile health platform Remote Assessment of Disease and Relapse (RADAR)-base as a toolbox to rapidly test the effect and response to NPIs intended to limit the spread of COVID-19.
METHODS
We analyzed data extracted from smartphone and wearable devices, and managed by the RADAR-base from 1062 participants recruited in Italy, Spain, Denmark, the United Kingdom, and the Netherlands. We derived nine features on a daily basis including time spent at home, maximum distance travelled from home, the maximum number of Bluetooth-enabled nearby devices (as a proxy for physical distancing), step count, average heart rate, sleep duration, bedtime, phone unlock duration, and social app use duration. We performed Kruskal-Wallis tests followed by post hoc Dunn tests to assess differences in these features among baseline, prelockdown, and during lockdown periods. We also studied behavioral differences by age, gender, BMI, and educational background.
RESULTS
We were able to quantify expected changes in time spent at home, distance travelled, and the number of nearby Bluetooth-enabled devices between prelockdown and during lockdown periods (P<.001 for all five countries). We saw reduced sociality as measured through mobility features and increased virtual sociality through phone use. People were more active on their phones (P<.001 for Italy, Spain, and the United Kingdom), spending more time using social media apps (P<.001 for Italy, Spain, the United Kingdom, and the Netherlands), particularly around major news events. Furthermore, participants had a lower heart rate (P<.001 for Italy and Spain; P=.02 for Denmark), went to bed later (P<.001 for Italy, Spain, the United Kingdom, and the Netherlands), and slept more (P<.001 for Italy, Spain, and the United Kingdom). We also found that young people had longer homestay than older people during the lockdown and fewer daily steps. Although there was no significant difference between the high and low BMI groups in time spent at home, the low BMI group walked more.
CONCLUSIONS
RADAR-base, a freely deployable data collection platform leveraging data from wearables and mobile technologies, can be used to rapidly quantify and provide a holistic view of behavioral changes in response to public health interventions as a result of infectious outbreaks such as COVID-19. RADAR-base may be a viable approach to implementing an early warning system for passively assessing the local compliance to interventions in epidemics and pandemics, and could help countries ease out of lockdown.

Identifiants

pubmed: 32877352
pii: v22i9e19992
doi: 10.2196/19992
pmc: PMC7527031
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

e19992

Subventions

Organisme : Medical Research Council
ID : MC_PC_17214
Pays : United Kingdom
Organisme : Department of Health
ID : RP-PG-0407-10314
Pays : United Kingdom
Organisme : Medical Research Council
ID : MR/M501633/2
Pays : United Kingdom
Organisme : Medical Research Council
ID : MR/K006584/1
Pays : United Kingdom
Organisme : Alzheimer's Society
ID : 171
Pays : United Kingdom
Organisme : Department of Health
ID : 05/40/04
Pays : United Kingdom
Organisme : Medical Research Council
ID : MC_PC_13041
Pays : United Kingdom
Organisme : Medical Research Council
ID : G0902393
Pays : United Kingdom

Informations de copyright

©Shaoxiong Sun, Amos A Folarin, Yatharth Ranjan, Zulqarnain Rashid, Pauline Conde, Callum Stewart, Nicholas Cummins, Faith Matcham, Gloria Dalla Costa, Sara Simblett, Letizia Leocani, Femke Lamers, Per Soelberg Sørensen, Mathias Buron, Ana Zabalza, Ana Isabel Guerrero Pérez, Brenda WJH Penninx, Sara Siddi, Josep Maria Haro, Inez Myin-Germeys, Aki Rintala, Til Wykes, Vaibhav A Narayan, Giancarlo Comi, Matthew Hotopf, Richard JB Dobson, RADAR-CNS Consortium. Originally published in the Journal of Medical Internet Research (http://www.jmir.org), 25.09.2020.

Références

JAMA. 2020 Apr 7;323(13):1239-1242
pubmed: 32091533
Lancet Respir Med. 2020 Apr;8(4):420-422
pubmed: 32085846
Annu Int Conf IEEE Eng Med Biol Soc. 2008;2008:1699-702
pubmed: 19163006
N Engl J Med. 2020 Apr 30;382(18):1708-1720
pubmed: 32109013
Med Eng Phys. 2008 May;30(4):466-77
pubmed: 17869159
BMC Psychiatry. 2019 Feb 18;19(1):72
pubmed: 30777041
JMIR Mhealth Uhealth. 2019 Aug 01;7(8):e11734
pubmed: 31373275
J Travel Med. 2020 Mar 13;27(2):
pubmed: 32052846
Lancet. 2020 Feb 15;395(10223):497-506
pubmed: 31986264
Lancet Glob Health. 2020 May;8(5):e641-e642
pubmed: 32199072
J Travel Med. 2020 May 18;27(3):
pubmed: 32181488
Sensors (Basel). 2014 Sep 16;14(9):17235-55
pubmed: 25230307
J Infect Dis. 2020 May 11;221(11):1757-1761
pubmed: 32067043
JAMA. 2020 Apr 14;323(14):1406-1407
pubmed: 32083643

Auteurs

Shaoxiong Sun (S)

The Department of Biostatistics and Health Informatics, Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, United Kingdom.

Amos A Folarin (AA)

The Department of Biostatistics and Health Informatics, Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, United Kingdom.
Institute of Health Informatics, University College London, London, United Kingdom.

Yatharth Ranjan (Y)

The Department of Biostatistics and Health Informatics, Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, United Kingdom.

Zulqarnain Rashid (Z)

The Department of Biostatistics and Health Informatics, Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, United Kingdom.

Pauline Conde (P)

The Department of Biostatistics and Health Informatics, Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, United Kingdom.

Callum Stewart (C)

The Department of Biostatistics and Health Informatics, Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, United Kingdom.

Nicholas Cummins (N)

Chair of Embedded Intelligence for Health Care & Wellbeing, University of Augsburg, Augsburg, Germany.

Faith Matcham (F)

The Department of Psychological Medicine, Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, United Kingdom.

Gloria Dalla Costa (G)

Neurorehabilitation Unit and Institute of Experimental Neurology, University Vita Salute San Raffaele, Istituto Di Ricovero e Cura a Carattere Scientifico Ospedale San Raffaele, Milan, Italy.

Sara Simblett (S)

The Department of Psychology, Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, United Kingdom.

Letizia Leocani (L)

Neurorehabilitation Unit and Institute of Experimental Neurology, University Vita Salute San Raffaele, Istituto Di Ricovero e Cura a Carattere Scientifico Ospedale San Raffaele, Milan, Italy.

Femke Lamers (F)

Department of Psychiatry, Amsterdam Public Health Research Institute and Amsterdam Neuroscience, Amsterdam University Medical Centre, Vrije Universiteit and GGZ inGeest, Amsterdam, Netherlands.

Per Soelberg Sørensen (PS)

Danish Multiple Sclerosis Centre, Department of Neurology, Copenhagen University Hospital Rigshospitalet, Copenhagen, Denmark.

Mathias Buron (M)

Danish Multiple Sclerosis Centre, Department of Neurology, Copenhagen University Hospital Rigshospitalet, Copenhagen, Denmark.

Ana Zabalza (A)

Multiple Sclerosis Centre of Catalonia (Cemcat), Department of Neurology/Neuroimmunology, Hospital Universitari Vall d'Hebron, Barcelona, Spain.

Ana Isabel Guerrero Pérez (AI)

Multiple Sclerosis Centre of Catalonia (Cemcat), Department of Neurology/Neuroimmunology, Hospital Universitari Vall d'Hebron, Barcelona, Spain.

Brenda Wjh Penninx (BW)

Department of Psychiatry, Amsterdam Public Health Research Institute and Amsterdam Neuroscience, Amsterdam University Medical Centre, Vrije Universiteit and GGZ inGeest, Amsterdam, Netherlands.

Sara Siddi (S)

Parc Sanitari Sant Joan de Déu, Fundació Sant Joan de Déu, Barcelona, Spain.
Centro de Investigación Biomédica en Red de Salud Mental, Madrid, Spain.
Universitat de Barcelona, Barcelona, Spain.

Josep Maria Haro (JM)

Parc Sanitari Sant Joan de Déu, Fundació Sant Joan de Déu, Barcelona, Spain.
Centro de Investigación Biomédica en Red de Salud Mental, Madrid, Spain.
Universitat de Barcelona, Barcelona, Spain.

Inez Myin-Germeys (I)

Centre for Contextual Psychiatry, Department of Neurosciences, Katholieke Universiteit Leuven, Leuven, Belgium.

Aki Rintala (A)

Centre for Contextual Psychiatry, Department of Neurosciences, Katholieke Universiteit Leuven, Leuven, Belgium.

Til Wykes (T)

The Department of Psychology, Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, United Kingdom.
South London and Maudsley National Health Services Foundation Trust, London, United Kingdom.

Vaibhav A Narayan (VA)

Janssen Research and Development LLC, Titusville, NJ, United States.

Giancarlo Comi (G)

Institute of Experimental Neurology, Istituto Di Ricovero e Cura a Carattere Scientifico Ospedale San Raffaele, Milan, Italy.

Matthew Hotopf (M)

The Department of Psychological Medicine, Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, United Kingdom.
South London and Maudsley National Health Services Foundation Trust, London, United Kingdom.

Richard Jb Dobson (RJ)

The Department of Biostatistics and Health Informatics, Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, United Kingdom.
Institute of Health Informatics, University College London, London, United Kingdom.
The RADAR-CNS Consortium, London, United Kingdom.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH